Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 5;34(1):108585.
doi: 10.1016/j.celrep.2020.108585.

Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer

Affiliations
Free article

Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer

Rayzel C Fernandes et al. Cell Rep. .
Free article

Abstract

Potent therapeutic inhibition of the androgen receptor (AR) in prostate adenocarcinoma can lead to the emergence of neuroendocrine prostate cancer (NEPC), a phenomenon associated with enhanced cell plasticity. Here, we show that microRNA-194 (miR-194) is a regulator of epithelial-neuroendocrine transdifferentiation. In clinical prostate cancer samples, miR-194 expression and activity were elevated in NEPC and inversely correlated with AR signaling. miR-194 facilitated the emergence of neuroendocrine features in prostate cancer cells, a process mediated by its ability to directly target a suite of genes involved in cell plasticity. One such target was FOXA1, which encodes a transcription factor with a vital role in maintaining the prostate epithelial lineage. Importantly, a miR-194 inhibitor blocked epithelial-neuroendocrine transdifferentiation and inhibited the growth of cell lines and patient-derived organoids possessing neuroendocrine features. Overall, our study reveals a post-transcriptional mechanism regulating the plasticity of prostate cancer cells and provides a rationale for targeting miR-194 in NEPC.

Keywords: FOXA1; lineage plasticity; miR-194; microRNA; neuroendocrine prostate cancer; post-transcriptional gene regulation; prostate cancer; transdifferentiation.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests The authors declare no competing interests.

Similar articles

  • Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
    Baca SC, Takeda DY, Seo JH, Hwang J, Ku SY, Arafeh R, Arnoff T, Agarwal S, Bell C, O'Connor E, Qiu X, Alaiwi SA, Corona RI, Fonseca MAS, Giambartolomei C, Cejas P, Lim K, He M, Sheahan A, Nassar A, Berchuck JE, Brown L, Nguyen HM, Coleman IM, Kaipainen A, De Sarkar N, Nelson PS, Morrissey C, Korthauer K, Pomerantz MM, Ellis L, Pasaniuc B, Lawrenson K, Kelly K, Zoubeidi A, Hahn WC, Beltran H, Long HW, Brown M, Corey E, Freedman ML. Baca SC, et al. Nat Commun. 2021 Mar 30;12(1):1979. doi: 10.1038/s41467-021-22139-7. Nat Commun. 2021. PMID: 33785741 Free PMC article.
  • Targeting RET Kinase in Neuroendocrine Prostate Cancer.
    VanDeusen HR, Ramroop JR, Morel KL, Bae SY, Sheahan AV, Sychev Z, Lau NA, Cheng LC, Tan VM, Li Z, Petersen A, Lee JK, Park JW, Yang R, Hwang JH, Coleman I, Witte ON, Morrissey C, Corey E, Nelson PS, Ellis L, Drake JM. VanDeusen HR, et al. Mol Cancer Res. 2020 Aug;18(8):1176-1188. doi: 10.1158/1541-7786.MCR-19-1245. Epub 2020 May 27. Mol Cancer Res. 2020. PMID: 32461304 Free PMC article.
  • The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
    Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, Olive V, Kobelev M, Okumura K, McCarthy D, Hanna MM, Mukherjee P, Sun B, Lee BR, Parker JB, Chakravarti D, Warfel NA, Zhou M, Bearss JJ, Gibb EA, Alshalalfa M, Karnes RJ, Small EJ, Aggarwal R, Feng F, Wang Y, Buttyan R, Zoubeidi A, Rubin M, Gleave M, Slack FJ, Davicioni E, Beltran H, Collins C, Kraft AS. Singh N, et al. Nat Commun. 2021 Dec 21;12(1):7349. doi: 10.1038/s41467-021-26901-9. Nat Commun. 2021. PMID: 34934057 Free PMC article.
  • Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer.
    Maylin ZR, Smith C, Classen A, Asim M, Pandha H, Wang Y. Maylin ZR, et al. Cells. 2024 Dec 3;13(23):1999. doi: 10.3390/cells13231999. Cells. 2024. PMID: 39682746 Free PMC article. Review.
  • Molecular model for neuroendocrine prostate cancer progression.
    Chen R, Dong X, Gleave M. Chen R, et al. BJU Int. 2018 Oct;122(4):560-570. doi: 10.1111/bju.14207. Epub 2018 Apr 24. BJU Int. 2018. PMID: 29569310 Review.

Cited by

Publication types

MeSH terms